CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Ahn, M-J [1 ]
Crino, L. [2 ]
Solomon, Ben [3 ]
Zhou, Caicun [4 ]
Ou, Sai-hong I. [5 ]
Selaru, P. [6 ]
Cohen, D. P. [6 ]
Bartlett, C. H. [7 ]
Kim, Dong-wan [8 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Osped S Maria Misericordia, Perugia, Italy
[3] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
[4] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[5] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Med Hematol Oncol, Orange, CA 92668 USA
[6] Pfizer Oncol, La Jolla, CA USA
[7] Pfizer Oncol, New York, NY USA
[8] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
poor performance status; brain metastases; elderly; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-036
引用
收藏
页码：S490 / S491
页数：2
相关论文
共 50 条
  • [31] PRELIMINARY EXPOSURE RESPONSE (ER) ANALYSIS OF CRIZOTINIB IN PATIENTS WITH ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER
    French, J.
    Tan, W. W.
    Kang, D.
    Bello, A.
    Selaru, P.
    Wilner, K.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S65 - S65
  • [32] Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance
    Xu, Haiyan
    Yang, Guangjian
    Yang, Lu
    Yang, Yaning
    Ma, Di
    Li, Junling
    Hao, Xuezhi
    Xing, Puyuan
    Wang, Yan
    THORACIC CANCER, 2019, 10 (05) : 1096 - 1102
  • [33] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [34] Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
    Kilickap, S.
    Ozturk, A.
    Karadurmus, N.
    Korkmaz, T.
    Yumuk, P.
    Cicin, I.
    Paydas, S.
    Cilbir, E.
    Sakalar, T.
    Uysal, M.
    Uskent, N.
    Demir, N.
    Sakin, A.
    Turhal, N.
    Keskin, S.
    Tural, D.
    Eralp, Y.
    Basal, F.
    Yasar, H.
    Sendur, M. A.
    Demirci, U.
    Cubukcu, E.
    Karaagac, M.
    Karaca, S.
    Tatli, A.
    Yetisyigit, T.
    Urvay, S.
    Gursoy, P.
    Uluc, B. Oyan
    Turna, Z.
    Kucukoner, M.
    Olmez, O.
    Cabuk, D.
    Seker, M.
    Unal, O.
    Meydan, N.
    Okutur, S.
    Tunali, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S477 - S478
  • [35] IMPACT OF CRIZOTINIB TREATMENT ON PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (QOL) IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Blackhall, F. H.
    Evans, T. L.
    Han, J.
    Salgia, R.
    Moro-Sibilot, D.
    Gettinger, S.
    Crino, L.
    Wilner, K.
    Reisman, A.
    Iyer, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 403 - 403
  • [36] Preliminary Characterization of Visual Events Reported by Patients (Pts) Receiving Crizotinib for the Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    Solomon, B.
    Chiappori, A.
    Lamb, A.
    Gawlicki, M. G.
    Kim, D. W.
    Park, K.
    Salgia, R.
    Wilner, K.
    Reisman, A.
    Petersen, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S231 - S231
  • [37] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [38] Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)
    Crino, L.
    Ahn, M-J.
    Han, J-Y.
    Liu, X.
    Ou, S-H. I.
    Shaw, A. T.
    Yang, P-C.
    Shi, Y-K.
    Lanzalone, S.
    Polli, A.
    Wilner, K. D.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer
    Yoshida, Tatsuya
    Oya, Yuko
    Tanaka, Kosuke
    Shimizu, Junichi
    Horio, Yoshitsugu
    Kuroda, Hiroaki
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    LUNG CANCER, 2016, 97 : 43 - 47
  • [40] Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
    Ock, Chan-Young
    Yoo, Shin-Hye
    Keam, Bhumsuk
    Kim, Miso
    Kim, Tae Min
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05): : 1116 - +
12345